Case report – Selective internal radiation therapy (SIRT) in a patient with hyperinsulinemic hypoglycemia due to a metastatic insulinoma with late onset of endocrine activity

Abstract

Insulinomas are the most common functioning pancreatic neuroendocrine tumors (NET), which can lead to hyperinsulinemic hypoglycemia. In advanced metastatic stages of the disease, the prognosis is poor. Patients with hormonally active insulinomas primarily present with features of neuroglycopenia. Transformation from a nonfunctional to a functional NET is rare. Here, we present a case of a 59-year-old male adult with a metastatic insulinoma and late onset of endocrine activity. Besides medical treatment with Diazoxide and small frequent feedings, continuous intravenous glucose application was eventually required to avoid hypoglycemia. Furthermore, we show that selective internal radiation therapy (SIRT) can be an effective therapeutic approach for symptom reduction in advanced metastatic disease.

Zusammenfassung

Insulinome gehören zu den häufigsten hormonaktiven neuroendokrinen Tumoren (NET) des Pankreas. Eine mögliche Komplikation stellt die hyperinsulinäme Hypoglykämie dar. Die Prognose im metastasierten Krankheitsstadium ist eingeschränkt. Patienten mit hormonproduzierenden Insulinomen werden klinisch meist mit Symptomen der Neuroglykopenie auffällig. Der Übergang eines nicht funktionellen NET in einen funktionellen NET ist selten. Wir stellen hier den Fall eines 59-jährigen Patienten mit metastasiertem Insulinom und Übergang in ein hormonaktives Stadium im späten Krankheitsverlauf vor. Trotz medikamentöser Therapie mit Diazoxid und häufigen kleinen Mahlzeiten war schließlich eine kontinuierliche intravenöse Glukosesubstitution notwendig, um Hypoglykämien zu vermeiden. Des Weiteren zeigen wir, dass die Selektive interne Radiotherapie (SIRT) eine mögliche Therapieoption zur Symptomkontrolle im metastasiertem Krankheitsstadium darstellt.

Schlüsselwörter

Darm - Gastro-entero-pankreatische Tumoren - Insulinom - SIRT - pNET - Hyperinsulinämie - Hypoglykämie

Keywords

gut - gastroentero-pancreatic tumors - insulinoma - SIRT - pNET - hyperinsulinemia - hypoglycemia

Publication History

Received: 25 August 2021

Accepted after revision: 03 November 2021

Article published online:
18 January 2022

• References

• 1 Vanderveen K, Grant C. Insulinoma. Cancer Treat Res 2010; 153: 235-252 DOI: 10.1007/978-1-4419-0857-5_13. (PMID: 19957228)
• 2 Service FJ, McMahon MM, OʼBrien PC. et al. Functioning Insulinoma – Incidence, Recurrence, and Long-Term Survival of Patients: A 60-Year Study. Mayo Clinic Proceedings 1991; 66: 711-719 DOI: 10.1016/s0025-6196(12)62083-7. (PMID: 1677058)
• 3 Gudala M, Ahmed M, Conroy R. et al. Insulinoma masquerading as a loss of consciousness in a teenage girl: case report and literature review. Int J Pediatr Endocrinol 2017; 2017: 13 DOI: 10.1186/s13633-017-0049-7. (PMID: 29075301)
• 4 de Herder WW, Niederle B, Scoazec JY. et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006; 84: 183-188 DOI: 10.1159/000098010. (PMID: 17312378)
• 5 Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol 2015; 33: 1855-1863 DOI: 10.1200/JCO.2014.60.2532. (PMID: 25918282)
• 6 Kessoku T, Kobayashi N, Yoneda M. et al. Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional Phenotype. Front Oncol 2020; 10: 555963 DOI: 10.3389/fonc.2020.555963.. (PMID: 33102220)
• 7 Juhlin CC, Skoglund S, Juntti-Berggren L. et al. Non-functioning neuroendocrine pancreatic tumors transforming to malignant insulinomas – four cases and review of the literature. Neuro Endocrinol Lett 2019; 40: 175-183 (PMID: 32087093)
• 8 Arslan MS, Ozbek M, Karakose M. et al. Transformation of nonfunctioning pancreatic tumor into malignant insulinoma after 3 years: an uncommon clinical course of insulinoma. Arch Endocrinol Metab 2015; 59: 270-272 DOI: 10.1590/2359-3997000000049. (PMID: 26154097)
• 9 Mele C, Brunani A, Damascelli B. et al. Non-surgical ablative therapies for inoperable benign insulinoma. J Endocrinol Invest 2018; 41: 153-162 DOI: 10.1007/s40618-017-0738-3. (PMID: 28755102)
• 10 Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135: 1469-1492 DOI: 10.1053/j.gastro.2008.05.047. (PMID: 18703061)
• 11 Scharf M, Mueller D, Koenig U. et al. Management of a metastasized high grade insulinoma (G3) with refractory hypoglycemia: case report and review of the literature. Pancreatology 2014; 14: 542-545 DOI: 10.1016/j.pan.2014.07.011.
• 12 Paprottka PM, Hoffmann RT, Haug A. et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol 2012; 35: 334-342 DOI: 10.1007/s00270-011-0248-1. (PMID: 21847708)
• 13 Devcic Z, Rosenberg J, Braat AJA. et al. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. J Nucl Med 2014; 55: 1404-1410 DOI: 10.2967/jnumed.113.135855. (PMID: 25012459)
• 14 Braat AJAT, Ahmadzadehfar H, Kappadath SC. et al. Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy. Cardiovasc Intervent Radiol 2020; 43: 246-253 DOI: 10.1007/s00270-019-02350-2. (PMID: 31646375)
• 15 King J, Quinn R, Glenn DM. et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113: 921-929 DOI: 10.1002/cncr.23685. (PMID: 18618495)